Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

TMCI - Treace Medical Concepts, Inc. Latest News | Finranks

Home

TMCI

(TMCI)

NMS – Real Time Price. Currency in USD

1.22

-0.06 (-4.69%)

At close: Mar 27, 2026, 4:00 PM EDT

1.23

+0.01 (0.82%)

After-hours: Mar 27, 2026, 6:37 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript

Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript

Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025.

Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference

Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies at the American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Las Vegas, Nevada from February 24-26, 2026.

First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review

First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review

First Eagle Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025. Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025.

Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results.

Videos

No Data

There is no data to display

Press releases

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025.

Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference

Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies at the American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Las Vegas, Nevada from February 24-26, 2026.

Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results.